Expanded Access Study of Palbociclib Plus Letrozole for Postmenopausal Women with HR+/HER2 − Advanced Breast Cancer in Latin America for Whom Letrozole Therapy is Deemed Appropriate
ConclusionPalbociclib in combination with letrozole was generally well tolerated with a clinically manageable safety profile; the observed ORR supported treatment benefit in Latin American women with HR+/HER2 − ABC.Trial RegistryClinicalTrials.gov, NCT02600923.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Argentina Health | Brazil Health | Breast Cancer | Cancer | Cancer & Oncology | Colombia Health | Drugs & Pharmacology | HER2 | Hormones | Mexico Health | Study | Thrombocytopenia | USA Health | Women